Press Digest: Wall Street Journal - March 1

Reata Pharmaceuticals

01/03/2023 06:57

March 1 (Reuters) - The following are the top stories in
the Wall Street Journal. Reuters has not verified these stories
and does not vouch for their accuracy.
    
    - The Food and Drug Administration on Tuesday approved Reata
Pharmaceuticals Inc's  RETA.O  drug Skyclarys, or omaveloxolone,
for treating the neurological disorder Friedreich's ataxia in
adults and adolescents age 16 and older.
    
    - A House committee on Tuesday took up legislation that
would effectively ban TikTok in the United States, but postponed
a vote on the measure until Wednesday. The bill would
effectively block U.S. interactions with the application.
    
    - Private-equity firm Apollo Global Management Inc  APO.N 
is in talks to acquire aerospace-parts maker Arconic Corp
 ARNC.N , according to people familiar with the matter. Apollo
submitted a bid in February, and has ensured debt financing. 
    
    - Goldman Sachs Group Inc  GS.N  Chief Executive David
Solomon said the company was "considering strategic
alternatives" for its consumer platforms business. Solomon,
however, didn't offer details.
        
  
        - Investcorp Holdings has closed on more than $1.2
billion  in commitments to invest in a North American
private-equity fund. It aims to make control investments in
middle-market services businesses. 
        
  
        - The Pentagon will have secure access to leading-edge
semiconductors manufactured at facilities receiving funding from
the $53 billion Chips Act, Commerce Secretary Gina Raimondo
said, ensuring the industry can supply the military with the
advanced chips it needs for modern weapons systems. 
        
  
        
  

 (Compiled by Bengaluru newsroom)
 ((globalnewsmonitoring@thomsonreuters.com))